Cargando…
Effective treatment of malignant hypercalcaemia with a single intravenous infusion of clodronate.
Thirty patients with hypercalcaemia due to malignancy that persisted following rehydration, were treated with a single dose of the bisphosphonate, clodronate. Clodronate (1.5 g) was administered intravenously in 500 ml normal saline over 4 h. Serum and urine biochemistry were measured before and aft...
Autores principales: | O'Rourke, N. P., McCloskey, E. V., Vasikaran, S., Eyres, K., Fern, D., Kanis, J. A. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1993
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968276/ https://www.ncbi.nlm.nih.gov/pubmed/8439504 |
Ejemplares similares
-
Treatment of malignant hypercalcaemia with clodronate.
por: Percival, R. C., et al.
Publicado: (1985) -
Treatment of malignant hypercalcaemia with aminohexane bisphosphonate (neridronate).
por: O'Rourke, N. P., et al.
Publicado: (1994) -
A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy.
por: Purohit, O. P., et al.
Publicado: (1995) -
Is there a dose response relationship for clodronate in the treatment of tumour induced hypercalcaemia?
por: Shah, S, et al.
Publicado: (2002) -
Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]
por: Powles, Trevor, et al.
Publicado: (2006)